Influenza vaccine with Surfacten, a modified pulmonary surfactant, induces systemic and mucosal immune responses without side effects in minipigs

Vaccine

Volumn 27, Issue 41, 2009, Pages 5620-5627

  Nishino, Maki ^a   Mizuno, Dai ^a   Kimoto, Takashi ^a   Shinahara, Wakako ^a   Fukuta, Akiho ^a   Takei, Tsunetomo ^a   Sumida, Kaori ^a   Kitamura, Seiichiro ^a   Shiota, Hiroshi ^a   Kido, Hiroshi ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Influenza vaccine; Mucosal adjuvant; Pulmonary surfactant

Indexed keywords

ANTIGEN; CYTOKINE; IMMUNOGLOBULIN A; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; SURFACTANT TA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; FEMALE; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; INFLAMMATORY CELL; INFLUENZA; LYMPH NODE; MINIPIG; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT MUCOSA;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; CROSS REACTIONS; HEMAGGLUTINATION INHIBITION TESTS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; NASAL MUCOSA; NEUTRALIZATION TESTS; PULMONARY SURFACTANTS; SWINE; SWINE, MINIATURE; VACCINES, SUBUNIT;

EID: 68949169091     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.07.024     Document Type: Article

References (33)

1. Simonsen L., Clarke M.J., Schonberger L.B., Arden N.H., Cox N.J., Fukuda K., et al. Prevention and early treatment of influenza in healthy adults. Vaccine 18 (2000) 957-1030
2. Wilde J.A., McMillan J.A., Serwint J., Butta J., O'Riordan M.A., and Steinhoff M.C. Effectiveness of influenza vaccine in health care professionals: a randomized trial. JAMA 281 (1999) 908-913
3. Bridges C.B., Thompson W.W., Meltzer M.I., Reeve G.R., Talamonti W.J., Cox N.J., et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA 284 (2000) 1655-1663
4. Jefferson T., Rivetti D., Rivetti A., Rudin M., Di Pietrantonj C., and Demicheli V. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet 366 (2005) 1165-1174
5. Clements M.L., Betts R.F., Tierney E.L., and Murphy B.R. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild type virus. J Clin Microbiol 24 (1986) 157-160
6. Tamura S.I., Asanuma H., Ito Y., Hirabayashi Y., Suzuki Y., Nagamine T., et al. Super cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine. Eur J Immunol 22 (1992) 477-481
7. Holmgren J., and Czerkinsky C. Mucosal immunity and vaccines. Nat Med 11 (2005) S45-S53
8. Briscoe J.H. Intranasal immunization with inactivated influenza virus vaccine in a boys' boarding school. Practitioner 214 (1975) 821-826
9. Davis S.S. Nasal vaccines. Adv Drug Deliv Rev 51 (2001) 21-42
10. CDC. Notice to readers: expansion of use of live, attenuated influenza vaccine (FluMist) to children age 2-4 years and other FluMist changes for the 2007-08 influenza seasons. MNWR 56 (2007) 1217-1219
11. Belshe R.B., Nichol K.L., Black S.B., Shinefield H., Cordova J., Walker R., et al. Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population age 5-49 years. Clin Infect Dis 39 (2004) 920-927
12. McCarthy M.W., and Kockler D.R. Trivalent intranasal influenza vaccine, live. Ann Pharmacother 38 (2004) 2086-2093
13. Durrer P., Gluck U., Spyr C., Lang A.B., Zurbriggen R., Herzog C., et al. Mucosal antibody response induced with a nasal virosome-based influenza vaccine. Vaccine 21 (2003) 4328-4334
14. Mutsch M., Zhou W., Rhodes P., Bopp M., Chen T., Linder T., et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 350 (2004) 896-903
15. Konishi M., Chida S., Shimada S., Kasai T., Murakami Y., Cho K., et al. Surfactant replacement therapy in premature babies with respiratory distress syndrome: factors affecting the response to surfactant and comparison of outcome from 1982-86 and 1987-91. Acta Paediatr Jpn 34 (1992) 617-630
16. Mizuno D., Ide-Kurihara M., Ichinomiya T., Kubo I., and Kido H. Modified pulmonary surfactant is a potent adjuvant that stimulates the mucosal IgA production in response to the influenza virus antigen. J Immunol 176 (2006) 1122-1130
17. Yuki Y., and Kiyono H. New generation of mucosal adjuvants for the induction of protective immunity. Rev Med Virol 13 (2003) 293-310
18. Ito T., Couceiro J.N.S.S., Klem S., Baun L.G., Krauss S., Castrucci M.R., et al. Molecular basis for the generation in pigs of influenza A virus with pandemic potential. J Virol 72 (1998) 7367-7373
19. Scholtissek C., Burger H., Kistner O., and Shortridge K.F. The nucleoprotein as a possible major factor in determining host specificity of influenza H3N2 viruses. Virology 147 (1985) 287-294
20. Webster R.G., Bean W.J., Gorman O.T., Chambers T.M., and Kawaoka Y. Evolution and ecology of influenza A viruses. Microbiol Rev 56 (1992) 152-179
21. Takagi T., Nishikawa K., Igarashi H., and Nokubi K. Problems on the definition of palatine tonsil-with special reference to the Suncus's tonsil. Jpn J Tonsil 24 (1985) 202-207
22. Perry M., and Whyte A. Immunology of the tonsils. Immunol Today 19 (1998) 414
23. Park H.S., Francis K.P., Yu J., and Cleary P.P. Membranous cells in nasal-associated lymphoid tissue: a portal of entry for the respiratory mucosal pathogen group A streptococcus. J Immunol 171 (2003) 2532-2537
24. Couch R.B., and Kasel J.A. Immunity to influenza in man. Annu Rev Microbiol 37 (1983) 529-549
25. Betts R.F., and Treanor J.J. Approaches to improved influenza vaccination. Vaccine 18 (2000) 1690-1695
26. King J.C., Gross P.A., Denning C.R., Gaerlan P.F., Wright P.F., and Quinnan G.V. Comparison of live and inactivated influenza vaccine in high risk children. Vaccine 5 (1987) 234-238
27. Subbarao K. Influenza vaccines: present and future advances. Virus Res 54 (1999) 349-373
28. Muszkat M., Ben Yehuda A., Schein M.H., Friedlander Y., Naveh P., Greenbaum E., et al. Local and systemic immune response in community dwelling elderly after intranasal or intramuscular immunization with inactivated influenza vaccine. J Med Virol 61 (2000) 100-106
29. Clements M.L., Betts R.F., and Murphy B.R. Advantage of live attenuated cold adaptive influenza A virus over inactivated influenza vaccine for A/Washington/80. Lancet 1 (1984) 705-708
30. Gurel O.M., Ikegami M., Chroneos Z.C., and Jobe A.H. Macrophage and type II cell catabolism of SP-A and saturated phosphatidylcholine in mouse lungs. Am J Physiol 280 (2001) L1266-L1272
31. Wright J.R., and Clements J.A. Metabolism and turnover of lung surfactant. Am Rev Respir Dis 136 (1987) 426-444
32. Larsen D.L., Karasin A., Zuckermann F., and Olsen C.W. Systemic and mucosal immune responses to H1N1 influenza virus infection in pigs. Vet Microbiol 74 (2000) 117-131
33. Lim Y.K., Takada A., Tanizaki T., Ozaki H., Okazaki K., and Kida H. Mucosal vaccination against influenza: Protection of pigs immunized with inactivated virus and ether-split vaccine. Jpn J Vet Res 48 (2001) 197-203